Becton Dickinson (BDX) has just launched its Elyra Thulium Fiber Laser System for kidney stone care, drawing positive clinical feedback on usability and safety, which now puts fresh attention on how investors view the stock.

Despite the Elyra launch and other recent updates, including a refreshed long term collaboration on infection prevention and new euro notes to refinance upcoming debt, the stock’s share price is still down 24.27% year to date, with a 19.10% decline over 90 days. However, the 1 year total shareholder return of 12.19% shows a more supportive picture over a longer stretch.

If kidney stone care and medical technology are on your radar, it can help to see what else is shaping healthcare AI, starting with 34 healthcare AI stocks

With Elyra, refreshed infection prevention partnerships, and fresh euro notes in the mix, BD trades about 22% below one intrinsic estimate. Is this healthcare staple on sale, or is the market already pricing in its next chapter?

Most Popular Narrative: 23.2% Undervalued

At a last close of $147.63 against a narrative fair value of $192.31, the current setup frames Becton Dickinson as materially out of step with that valuation story.

The pending separation of the Biosciences and Diagnostic Solutions business will transform BD into a pure-play medical technology leader with a consumables-heavy portfolio (>90% of revenue). This is expected to enable higher cash flow predictability and margin improvement, while anticipated aggressive share buybacks directly support EPS growth.

Want to see why this valuation leans so heavily on future earnings power Rather than top line momentum, the narrative focuses on rising margins, higher cash flow per share and a richer profit multiple that leans closer to high growth peers than to the broader market.

Result: Fair Value of $192.31 (UNDERVALUED)

However, the story can change quickly if tariff and trade pressures deepen, or if the planned Biosciences and Diagnostics separation brings higher costs and slower execution.

Next Steps

If this mix of optimism and concern feels familiar, take action while the details are fresh and carefully weigh the balance of 5 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that might suit your goals better, so keep broadening your watchlist with fresh angles.

• Spot potential value plays early by scanning 48 high quality undervalued stocks, where you can see which companies currently line up with quality and pricing filters.
• Strengthen your portfolio’s foundations by checking the solid balance sheet and fundamentals stocks screener (46 results) so you focus on companies with support from their financial position.
• Catch promising stories before they hit the spotlight by browsing the screener containing 21 high quality undiscovered gems and see which quieter stocks line up with your criteria.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.